Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

IDO activity and expression measured by kynurenine/tryptophan ratio in serum and by PCR in peripheral blood mononuclear cells.

Outcome Description:

Indoleamine 2,3 -dioxygenase (IDO) activity in patients with CLL was measured by the serum kynurenine/tryptophan (kyn/trp) ratio and - the expression of INDO (encoding IDO enzyme) and INDOL1 (encoding IDO2 enzyme) genes in peripheral blood mononuclear cells via TaqMan real-time PCR.

Outcome Time Frame:

3 months

Safety Issue:

No

Principal Investigator

Marjatta Sinisalo, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Tampere University Hospital

Authority:

Finland: Finnish Medicines Agency

Study ID:

CLL-IDO

NCT ID:

NCT01397916

Start Date:

February 2010

Completion Date:

December 2010

Related Keywords:

• CLL
• CLL
• IDO
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

Name	Location